Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Guadecitabine - Astex Pharmaceuticals

Next Previous
Drug Profile

Guadecitabine - Astex Pharmaceuticals

Alternative Names: Decitabine deoxyguanosine; Decitabine deoxyguanosine dinucleotide; DNMT-inhibitor-SGI-110; Guadecitabine-sodium; S-110; SGI-110

Latest Information Update: 05 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SuperGen
  • Developer Astex Pharmaceuticals; AstraZeneca; Big Ten Cancer Research Consortium; Fox Chase Cancer Center; Indiana University School of Medicine; John Hopkins University; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); University of Southern California; Weill Cornell Medical College
  • Class Antineoplastics; Aza compounds; Furans; Purine nucleotides; Small molecules; Triazines
  • Mechanism of Action Antimetabolites; DNA cytosine 5 methyltransferase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Bladder cancer; Cholangiocarcinoma; Chondrosarcoma; Chronic myelomonocytic leukaemia; Colorectal cancer; Fallopian tube cancer; Gastrointestinal stromal tumours; Germ cell and embryonal neoplasms; Germ cell cancer; Liver cancer; Malignant melanoma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Phaeochromocytoma; Renal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; T-cell lymphoma; Testicular cancer; Urogenital cancer

Most Recent Events

  • 05 Feb 2026 Discontinued - Phase-I for Cholangiocarcinoma (Combination therapy, Late-stage disease) in USA (SC)
  • 05 Feb 2026 Discontinued - Phase-I for Colorectal cancer (Metastatic disease, In the elderly, Combination therapy, Second-line therapy or greater, In adults) in USA (SC)
  • 05 Feb 2026 Discontinued - Phase-I for Germ cell and embryonal neoplasms (Second-line therapy or greater, Combination therapy) in USA (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top